产品说明书

Irinotecan HCl Trihydrate

Print
Chemical Structure| 136572-09-3 同义名 : 盐酸伊立替康三水合物 ;CPT-11 hydrochloride trihydrate;Irinotecan (hydrochloride hydrate);CPT-11 HCl Trihydrate;Irinotecan HCl Trihydrate;(+)-Irinotecan hydrochloride trihydrate
CAS号 : 136572-09-3
货号 : A244220
分子式 : C33H45ClN4O9
纯度 : 98%
分子量 : 677.185
MDL号 : MFCD01765731
存储条件：

粉末 Keep in dark place,Inert atmosphere,Room temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 50 mg/mL(73.84 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 1.5 mg/mL(2.22 mM)

无水乙醇: 3 mg/mL(4.43 mM)，配合低频超声助溶，注意：无水乙醇开封后，易挥发，也会吸收空气中的水分，导致溶解能力下降，请避免使用开封较久的乙醇
动物实验配方：

IP 2% DMSO+water 8 mg/mL clear

PO 0.5% CMC-Na 48 mg/mL suspension

生物活性
靶点

  • Topo I
描述 Irinotecan hydrochloride trihydrate ((+)-Irinotecan hydrochloride trihydrate), a potent topoisomerase I inhibitor, exhibits antitumor properties[1].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00483834 Colorectal Cancer Phase 2 Completed - Canada, Ontario ... 展开 >> Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT03245450 Refractory or Recurrent Solid ... 展开 >>Tumors Rhabdomyosarcoma Non-Rhabdomyosarcoma Soft Tissue Sarcoma Ewing Sarcoma 收起 << Phase 1 Phase 2 Recruiting June 30, 2021 Germany ... 展开 >> Uniklinik RWTH Aachen Kinderklinik Recruiting Aachen, Germany Charite Virchow Kinderklinik - CC17 Recruiting Berlin, Germany Uniklinik Essen AoR Kinderklinik Recruiting Essen, Germany Klinik fur Kinder und Jugendmed - KKJM Recruiting Frankfurt, Germany Uniklinik Freiburg Kindermedizin Klinik IV Recruiting Freiburg, Germany Uniklinik Gottingen Kindermedizin Recruiting Gottingen, Germany Kinderklinik Muenchen Schwabing Not yet recruiting Muenchen, Germany 收起 <<
NCT02015754 Colorectal Cancer Phase 2 Completed - United States, Maryland ... 展开 >> The Johns Hopkins Hospital Baltimore, Maryland, United States, 21287 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.48mL

0.30mL

0.15mL

7.38mL

1.48mL

0.74mL

14.77mL

2.95mL

1.48mL
参考文献

[1]Morales C, et al. Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor. J Neurooncol. 2002 Feb;56(3):219-26.

[2]Pavillard V, et al. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol. 2002 Apr;49(4):329-35. Epub 2002 Jan 30.

[3]Allegrini G, et al. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol. 2004 Mar;53(3):261-6. Epub 2003 Dec 5.